FOLH1 and neoplasm: In a pretherapeutic comparative dosimetry study of 177Lu-labeled rhPSMA-7.3 and PSMA I&T on a small patient cohort (n = 6, intraindividual comparison), an approximately 2.4-fold higher mean absorbed dose for tumor lesions of the radiohybrid ligand was found, consistent with the preclinical observations (14).